Thailand is examining the feasibility of adopting new global guidelines on long-acting HIV prevention, following the World Health Organisation's (WHO) launch of its latest recommendations for ...

Two monoclonal antibodies appeared safe and tolerable when administered alone or in combination to newborns exposed to HIV, according to a proof-of-concept study presented at the International AIDS ...

Will we-the-quails unite to lift the net or wither away the gains made in AIDS response? By SHOBHA SHUKLA, BOBBY RAMAKANT ...

Participants who initiated long-acting cabotegravir-rilpivirine had a high rate of adherence and virologic suppression, with ...

WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

For more than two decades, the global community has united to fight the HIV pandemic, achieving remarkable progress. New HIV transmissions and AIDS-related deaths have dropped significantly, and ...

A new injectable drug known as lenacapavir could change how millions of people across the world and Africa in particular access HIV protective drugs, which historically have hard to come by. Presented ...

Newsday Zimbabwe HEALTH and Child Care minister Douglas Mombeshora has reaffirmed the country’s commitment to advancing HIV research, treatment and global collaboration. He said this during the ...

In lead up to world's largest HIV science conference (13th International AIDS Society (IAS) Conference on HIV Science (IAS 2025), let us remember when first few people with HIV were diagnosed in ...

Researchers wanted to provide insight into the relative clinical value of Apretude and lenacapavir compared with no ...

After the virologic failure of cabotegravir/rilpivirine and despite dual-class resistance mutations, Canadian doctors have ...

However, despite the Senate's decision to protect Pepfar from President Trump's proposed $400 million (Sh51.6 billion) ...